PLSE logo

PLSE
Pulse Biosciences Inc

2,047
Mkt Cap
$1.56B
Volume
143,560.00
52W High
$26.30
52W Low
$12.56
PE Ratio
-21.30
PLSE Fundamentals
Price
$23.00
Prev Close
$23.03
Open
$22.29
50D MA
$19.71
Beta
1.43
Avg. Volume
261,776.74
EPS (Annual)
-$1.08
P/B
19.35
Rev/Employee
$3,017.24
$852.13
Loading...
Loading...
News
all
press releases
Pulse Biosciences to Present at the 25th Annual Needham Virtual Healthcare Conference
Pulse Biosciences, Inc. (Nasdaq: PLSE), pioneer of the novel nPulse platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA), today announced plans to present at the upcoming 25th Annual...
Business Wire·3d ago
News Placeholder
More News
News Placeholder
Pulse Biosciences (NASDAQ:PLSE) Shares Down 7% - What's Next?
Pulse Biosciences (NASDAQ:PLSE) Stock Price Down 7% - Here's What Happened...
MarketBeat·6d ago
News Placeholder
PLSE Accelerates Cardiac Catheter Program After Breakthrough AFib Data
Pulse Biosciences pivots to its nPulse AFib system after strong clinical results, ramping investment to accelerate development and future commercialization.
Zacks·10d ago
News Placeholder
Pulse Biosciences Touts 96% 12-Month Rhythm Control, Targets Q2 Start for U.S. AF IDE Study
Pulse Biosciences (NASDAQ:PLSE) executives highlighted recent clinical results for the company's nanosecond pulsed field ablation (nsPFA) technology, outlined plans for a U.S. investigational device...
MarketBeat·15d ago
News Placeholder
Pulse Biosciences (NASDAQ:PLSE) Stock Price Passes Above Fifty Day Moving Average - What's Next?
Pulse Biosciences (NASDAQ:PLSE) Stock Price Crosses Above 50-Day Moving Average - Here's What Happened...
MarketBeat·18d ago
News Placeholder
Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data
Pulse Biosciences, Inc. (Nasdaq: PLSE), pioneer of the novel nPulse platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA), today announced a new strategic alignment to prioritize and...
Business Wire·19d ago
News Placeholder
Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse Technology
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse technology using its proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) energy, today announced first patient...
Business Wire·24d ago
News Placeholder
Pulse Biosciences (NASDAQ:PLSE) Trading 8% Higher - What's Next?
Pulse Biosciences (NASDAQ:PLSE) Shares Up 8% - Should You Buy...
MarketBeat·26d ago
News Placeholder
Pulse Biosciences Announces Clinical Data From nPulse Vybrance System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse technology using proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) energy, today announced clinical data on...
Business Wire·27d ago
News Placeholder
Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse technology using its proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) energy, today announced plans to...
Business Wire·1mo ago
<
1
2
...
>

Latest PLSE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.